High-Risk Skin Cancers With Atezolizumab Plus NT-I7
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test whether the addition of NT-I7 to atezolizumab provides
clinically meaningful outcomes for patients with anti-PD-1/PD-L1 naive or relapsed/refractory
high-risk melanoma, Merkel Cell Carcinoma (MCC) and cutaneous Squamous Cell Carcinoma (cSCC)